baroguaranig parano iroanar

CURANAIL 5% NAIL LACQUER (AMOROLFINE HYDROCHLORIDE) PL 10590/0049

UKPAR

TABLE OF CONTENTS

| Lay Summary | Page 2 |
|-------------------------------------------|---------|
| Scientific discussion | Page 3 |
| Steps taken for assessment | Page 20 |
| Steps taken after authorisation – summary | Page 21 |
| Summary of Product Characteristics | Page 22 |
| Product Information Leaflet | Page 27 |
| Labelling | Page 30 |

Medicines and Healthcare products Regulatory Agency



CURANAIL 5% NAIL LACQUER PL 10590/0049

LAY SUMMARY

The MHRA granted Galderma (UK) Limited a Marketing Authorisation (licence) for the medicinal product Curanail 5% nail Lacquer (PL 15909/0049) on 7th April 2006. This medicine which is available from Pharmacies is used to treat mild fungal infections of the nail in up to 2 nails.

Curanail 5% Nail Lacquer contains the active ingredient amorolfine (as the hydrochloride), which is one of a group of medicines known as anti-fungals, which kill a wide variety of fungi which can cause infections.

This new product is a duplicate of a previously granted application for Loceryl Nail Lacquer 5% (PL 10590/0042) held by Galderma (UK) Limited which is available on prescription for more serious fungal nail infections. Curanail 5% Nail Lacquer is for milder fungal infections of the nail and has been granted a different legal supply classification, which means it can be sold in pharmacies.

No new or unexpected safety concerns arose from these applications. It was, therefore, judged that the benefits of Curanail 5% Nail Lacquer being available from a pharmacy outweigh the risks. Hence a Marketing Authorisation has been granted.



CURANAIL 5% NAIL LACQUER PL 10590/0049

SCIENTIFIC DISCUSSION

TABLE OF CONTENTS

| Introduction | Page 4 |
|-------------------------------------------------|---------|
| Pharmaceutical assessment | Page 5 |
| Preclinical assessment | Page 6 |
| Clinical assessment | Page 7 |
| Overall conclusions and risk benefit assessment | Page 19 |

INTRODUCTION

The UK granted a marketing authorisation for the medicinal product Curanail 5% Nail Lacquer (PL 10590/0049) to Galderma (UK) Limited on 7th April 2006. The product is available in Pharmacies (P).

The application was submitted according to article 10.c [formerly article 10.1(a)(i)] of Directive 2001/83/EC, cross-referring to Loceryl Nail Lacquer 5% (PL 10590/0042). The cross-reference application was granted on 19th April 1999 as a change of ownership from PL 00031/0285, held by Roche Products Limited which was itself granted a marketing authorisation for on 4th July 1991.

No new quality data was submitted nor was it necessary for this simple application, as the data is identical to that of the previously granted cross-reference product. As the cross-reference product was granted prior to the introduction of current legislation, no public assessment report was generated for it.

The product contains the active ingredient amorolfine hydrochloride which is a broad spectrum topical antimycotic agent that has both fungistatic and fungicidal activity against all pathogens of nail mycosis. The product is indicated for the treatment of mild cases of distal and lateral subungual onychomycoses caused by dermatophytes, yeasts and moulds limited up to 2 nails.



PHARMACEUTICAL ASSESSMENT

This abridged simple application is associated with a reclassification application – see medical assessment for the joint medical/ pharmaceutical assessment.

The company has submitted an expert statement confirming that all pharmaceutical aspects are the same as the cross reference product. The Marketing Authorisation Application form has been updated to reflect the current granted licence. The Drug Substance Specification, method of manufacture and Finished Product Specification are consistent with the current granted MA and this is satisfactory

Conclusion

This MA may be approved as a P product.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

